Lacosamide Provides Benefit as Second-Line Treatment for Refractory Trigeminal Neuralgia
A recent report highlights the potential benefits of lacosamide as a second-line treatment for refractory trigeminal neuralgia. Trigeminal neuralgia is a chronic condition characterized by severe facial pain, often resistant to conventional treatments. The study examined the efficacy and safety of lacosamide, an antiepileptic drug, in a group of patients who had not responded to initial therapy. The findings showed that lacosamide demonstrated significant pain relief and improved quality of life in this population. Additionally, the drug was well-tolerated with only a few reported adverse events. These results suggest that lacosamide could be a valuable option for individuals with refractory trigeminal neuralgia who have not achieved adequate relief with other treatments.